Dr. Primo Lara reviewed kidney cancer therapies, noting surgery as standard for Stage 1 with high survival. For Stages 2-3, adjuvant pembrolizumab improves outcomes. Metastatic cases use nivo-ipi or pembro-axi combos. He stressed risk-based, individualized care and ongoing trials for future options.